Restricted accessOtherFirst published online 1995-3
Is the 'A' in atypical really due to α2-adrenoceptor antagonism? A comment on: Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?
Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S., The Olanzapine HGAD Study Group (1995) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (in press)
2.
Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. (1995) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology (in press)
3.
Moore N.A., Tye N.C., Axton M.S., Risius F.C. (1992) The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther262: 545-551
4.
Moore N.A., Rees G., Sanger G., Tye N.C. (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol5: 196-202
5.
Nutt D.J. (1994) Putting the 'A' in atypical: does α2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics ? J Psychopharmacol8: 193-195
